CHL1 and non-small cell lung carcinoma: Interestingly, as shown in Fig. 3C, miR-338-3p could be significantly enriched in the MAPK signaling pathway, suggesting that miR-338-3p might directly target CHL1 by the MAPK signaling pathway to inhibit NSCLC metastasis.